FORM 990, PART I, LINE 1 AND PART III, LINE 1 - MISSION STATEMENT |
TO PROVIDE SUPPORT TO THE TEXAS MEDICAL CENTER, A TEXAS NONPROFIT CORPORATION DESCRIBED IN IRC SECTION 501(C)(3). |
FORM 990, PART III, LINE 4 - PROGRAM SERVICE ACTIVITIES |
LINE 4A: PROGRAM SERVICE ACTIVITY #1 BARDA, THE BIOMEDICAL ADVANCED RESEARCH & DEVELOPMENT AUTHORITY, PART OF THE US DEPT HEALTH & HUMAN SERVICES. THIS GRANT PROVIDES AN INTEGRATED, SYSTEMATIC, APPROACH TO THE DEVELOPMENT OF THE NECESSARY VACCINES, DRUGS, THERAPIES & DIAGNOSTIC TOOLS FOR PUBLIC HEALTH MEDICAL EMERGENCIES, SUCH AS CHEMICAL BIOLOGICAL, RADIOLOGICAL, AND NUCLEAR ACCIDENTS, INCIDENTS AND ATTACHES; PANDEMIC INFLUENZA, AND EMERGING INFECTIOUS DISEASES. TOGETHER WITH ITS INDUSTRY PARTNERS, BARDA PROMOTES THE ADVANCEMENT OF MEDICAL COUNTERMEASURES TO PROTECT AMERICANS AND RESPOND TO 21ST CENTURY HEALTH SECURITY THREATS. LINE 4B: PROGRAM SERVICE ACTIVITY #2 TMC ACT IS THE ONLY CANCER THERAPEUTICS ACCELERATOR BUILDING RELATIONSHIPS WITH HEALTH CARE PROFESSIONALS LEADING THE WORLD'S BEST CANCER TREATMENT PROGRAMS AT THE TEXAS MEDICAL CENTER MEMBER HOSPITALS. THE ACT PROGRAM IS A CPRIT FUNDED ACCELERATOR LAUNCHED IN COLLABORATION WITH THE GULF COAST CONSORTIUM (GCC) AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH (UTMB) TO SUPPORT TEXAS-BASED BIOTECH ENTREPRENEURS, RESEARCHERS CONTEMPLATING TRANSLATIONS, AND INTERNAL COMPREHENSIVE DRUG DEVELOPMENT PROGRAMS. ACT IS A COMPREHENSIVE NINE-MONTH PROGRAM DESIGNED TO ENHANCE ONCOLOGY BIOTECH ENTREPRENEURSHIP TRAINING AND DRUG DEVELOPMENT PROGRAMS IN TEXAS. THE PROGRAM WILL SIMULTANEOUSLY PROVIDE TEXAS RESEARCHERS AND STARTUP COMPANIES WITH INTEGRATED TRAINING, RESOURCES, AND MENTORING IN ORDER TO HELP ADVANCE INNOVATIVE CANCER THERAPY DISCOVERIES AND DEVELOPMENT PROGRAMS, ULTIMATELY LEADING TO NEW APPROACHES AND THERAPIES FOR CANCER PATIENTS. LINE 4B: PROGRAM SERVICE ACTIVITY #3 INNOVATE UK, A COUNCIL OF UK RESEARCH AND INNOVATION IS AN AGREEMENT BETWEEN INNOVATE UK AND TEXAS MEDICAL CENTER. THE GLOBAL INCUBATOR PROGRAM IS AN EXCHANGE PROGRAM FOR SMES USING INCUBATORS AS SOFT LANDING TO BREAK DOWN BARRIERS AND ENABLE INNOVATIVE SMES TO MORE EASILY BUILD COLLABORATIONS AND PARTNERSHIPS AND EXPLORE THE POTENTIAL OF OVERSEAS MARKETS IN ORDER TO ADVANCE HEALTH, MEDICINE AND RESEARCH. THIS PROGRAM WILL ALLOW THE TEXAS MEDICAL CENTER TO ADVANCE ITS MISSION BY LEVERAGING ITS INNOVATION FACTORY TO PROVIDE TRAINING FOR MEDICAL DEVICE AND DIGITAL HEALTH START-UP COMPANIES. |
FORM 990, PART VI, SECTION A, LINE 11 - 990 REVIEW PROCESS |
THE PREPARER REVIEWS THE FORM 990 WITH THE CFO. THE FORM 990 IS DISTRIBUTED TO AND REVIEWED BY THE AUDIT COMMITTEE. THE FINAL 990 IS MADE AVAILABLE TO THE BOARD OF DIRECTORS PRIOR TO FILING. |
FORM 990, PART VI, SECTION B, LINE 12C - CONFLICT OF INTEREST COMPLIANCE |
CONFLICT OF INTEREST STATEMENTS ARE COMPLETED ANNUALLY BY THE BOARD OF DIRECTORS, OFFICERS AND KEY EMPLOYEES. THE STATEMENTS ARE REVIEWED BY THE LEGAL DEPARTMENT. IF A CONFLICT WERE TO ARISE, THE BOARD MEMBER WOULD BE REQUIRED TO DISMISS HIMSELF/HERSELF FROM ANY DISCUSSIONS OR DECISIONS REGARDING THE AREA OF CONFLICT. |
FORM 990, PART VI, SECTION B, LINE 15 - COMPENSATION APPROVAL |
THE TMC BOARD OF DIRECTOR'S MEETS ANNUALLY AS PART OF THE PRESIDENT'S ANNUAL REVIEW AND COMPENSATION. THE BOARD REVIEWS THE PERFORMANCE OF THE COMPANY AND THE PRESIDENT'S PERFORMANCE TO DECIDE COMPENSATION. DURING THIS PROCESS, THE BOARD ALSO RECEIVES PERFORMANCE REVIEW AND COMPENSATION INFORMATION ON EACH MEMBER OF THE EXECUTIVE LEADERSHIP TEAM. |
FORM 990, PART VI, SECTION B, LINE 19 - PUBLIC DISCLOSURE |
TEXAS MEDICAL CENTERS FOUNDATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. |